Pharmaceutical industry growth
The value of the global pharmaceutical market is expected to increase 4–6% on a constant-dollar basis in 2010 and reach $825 billion, according to estimates issued in October 2009 by IMS, the research firm's latest estimates. IMS projects comparable growth in the near term, with the global pharmaceutical market increasing at a compound annual growth rate of 4–7% through 2013, when the market is expected to reach in excess of $975 billion.
The US pharmaceutical market is expected to increase 4.5–5.5% in 2009 and 3.5% in 2010, according to October 2009 estimates by IMS. Although prospects in the US market are better than earlier projected, the global market will continue to be pressured by the patent expiry of innovator drugs and fewer new product introductions over the several years. This imbalance is the primary factor limiting global pharmaceutical market growth to the mid-single digits through 2013, according to IMS.
Products now generating $137 billion in value are expected to lose patent protection through 2013. Some key patent expiries include Lipitor (atorvastatin) by Pfizer (New York), Plavix (clopidogrel) by sanofi-aventis (Paris) and Bristol-Myers Squibb (New York), and Seretide/Advair (salmeterol and fluticasone) by GlaxoSmithKline (London). Lipitor, Plavix, and Seretide were respectively the number one, two, and fourth-selling drugs in 2008 with respective global sales of $13.7 billion, $8.6 billion, and $7.7 billion and respective US sales of $7.8 billion, $4.9 billion, and $4.4 billion.
Despite economic conditions affecting some emerging markets, projected growth in the BRIC countries, Turkey, South Korea, and Mexico is still strong as these markets are expected in aggregate to increase by 12–14% in 2010, and 13–16% through 2013, according to IMS. China's pharmaceutical market, alone, is expected to increase in excess of 20% per year and contribute 21% of overall global pharmaceutical growth in 2013.